Enhancing Tumoricidal Activity of Natural Killer (NK) Cells by Dietary Components for Cancer Prevention (R21) | Apply Online

FAQs: NCI PA-08-132 - Enhancing Tumoricidal Activity of Natural Killer (NK) Cells by Dietary Components for Cancer Prevention (R21)

What is PA-08-132 focused on?

PA-08-132 is a National Cancer Institute (NCI) funding opportunity focused on early-stage, exploratory research that tests how specific dietary components can enhance the tumor-killing (tumoricidal) function of natural killer (NK) cells in ways that matter for cancer prevention.

What is the overall goal of the research supported by this opportunity?

The goal is to move beyond broad statements like "diet affects immunity" and instead identify physiologically meaningful effects of particular food-derived components on NK cell tumoricidal activity. Projects are expected to generate practical, biologically grounded parameters (how much and how long) and to explain mechanisms (how and why NK cell function changes).

What type of grant mechanism is used?

This opportunity uses the NIH Exploratory/Developmental Grant (R21) mechanism, which is typically used for innovative, higher-risk projects aimed at proof-of-concept or foundational data rather than a fully mature, large-scale research program.

Is there a companion opportunity for larger projects?

Yes. The announcement notes a companion funding opportunity with the same scientific scope that uses the R01 mechanism (PA-08-131), which is generally more appropriate for larger, more established lines of investigation.

What is a key expectation for studies under this FOA?

A key expectation is that projects define the minimum effective dose and the minimum effective duration of exposure for the dietary component(s) being studied. Applicants are expected to determine how much of a dietary factor is required, and over what timeframe, to produce a measurable and meaningful increase in NK cell tumoricidal activity in living systems.

Does the FOA require mechanistic research, or are outcome-only studies acceptable?

The FOA calls for mechanistic work to explain how and why dietary components alter NK cell function. The mechanism component is intended to be specific (molecular and cellular pathways), not vague or purely descriptive, and should connect dietary exposure to changes in NK cell-mediated killing.

Are in vivo studies required?

Yes. To be considered responsive, proposed studies must include in vivo work in animals and/or humans.

Are in vitro (cell culture) studies allowed?

In vitro studies are allowed only as supporting evidence to interpret or validate in vivo findings. Projects that are cell culture-only, or where in vitro work is the primary thrust, do not fit the intent of this FOA.

What kinds of in vitro approaches does the FOA mention as useful supports?

The FOA notes that carefully chosen in vitro systems can clarify molecular mechanisms when they are directly tied to the in vivo question. Examples include highly purified immune cell populations, defined tumor target cells such as RMA-S (noted for lacking class I MHC expression), target-cell-free systems, or single-cell assays.

What is the relevance of RMA-S target cells in the examples provided?

RMA-S cells are mentioned as defined tumor target cells that lack class I MHC expression, a feature relevant to NK cell recognition. In the FOA context, such targets can help probe the molecular basis of diet-induced changes in NK cell tumoricidal activity when used to support in vivo findings.

What mechanistic readouts or targets is NCI signaling interest in?

The FOA highlights several mechanistic categories, including: (1) interactions between NK cell tumoricidal receptors and ligands on cancer cells, (2) changes in production of tumoricidal cytokines such as interferon-gamma (IFN-g), and (3) modulation of NK cell cytotoxic machinery involved in direct killing.

Which cytotoxic mediators are specifically called out?

The FOA specifically calls out release of lytic granules and their contents, including granulysin, perforin, and serine proteases known as granzymes.

What does the FOA mean by connecting diet to "physiological significance"?

Within this FOA, "physiological significance" refers to identifying dietary component effects that are meaningful in living systems (animals and/or humans), including realistic dose and exposure durations that produce measurable increases in NK cell tumoricidal activity that could plausibly translate into reduced cancer risk.

Is the emphasis on cancer treatment or cancer prevention?

The through-line is prevention. The FOA emphasizes establishing how diet-driven changes in NK cell tumoricidal activity could plausibly contribute to reduced cancer development or progression risk, supported by in vivo data and complemented by mechanistic assays.

What is the award ceiling listed for this opportunity?

The award ceiling is listed as $200,000 in the provided source information.

Is cost sharing or matching required?

No. The opportunity states there is no cost sharing or matching requirement.

What CFDA numbers are associated with this opportunity?

The opportunity is listed under CFDA 93.393 (Cancer Cause and Prevention Research) and 93.396 (Cancer Biology Research).

Who is eligible to apply based on the provided information?

Eligibility is described as broad and includes private and public institutions of higher education, nonprofit organizations (including 501(c)(3) and certain non-501(c)(3) nonprofits), small businesses, for-profit organizations, state governments, and additional entities such as eligible federal agencies and non-U.S. (foreign) organizations, as well as regional organizations and U.S. territories or possessions.

Is this funding opportunity still active?

No. The FOA was posted April 2, 2008, with an original and current closing date of May 7, 2011, and an archive date of June 7, 2011. Based on those dates, it is no longer active, but it can still serve as a reference for NCI priorities and the types of research encouraged during that period.

What kinds of projects would be considered non-responsive based on the description?

Projects that do not include in vivo work (animals and/or humans) and projects where in vitro/cell culture experiments are the primary thrust (or the only experiments) are explicitly described as not fitting the intent of the FOA.

How should applicants think about integrating in vivo and in vitro work under this FOA?

The FOA expects the central evidence to come from in vivo studies, with in vitro work used in a targeted way to clarify or validate mechanisms directly related to the in vivo findings (for example, receptor-ligand interactions, cytokine output like IFN-g, and granule-mediated killing machinery involving perforin/granzymes/granulysin).

What is the practical deliverable NCI appears to want from funded R21 projects in this area?

Based on the description, NCI is seeking credible, in vivo-grounded proof-of-concept evidence that specific dietary components can enhance NK cell-mediated tumor surveillance, along with practical dose and timing parameters and mechanistic explanations that link dietary exposure to changes in NK cell tumoricidal function.